XXXX due to @entity989 ( @entity989 ) in New Zealand: a 22-year review.

@entity1 @entity5394 @entity227 @entity989 @entity4064
AIM: To evaluate @entity989 ( @entity989 )-related @entity227 in New Zealand @entity1 . METHODS: 22-year retrospective review of medical records of @entity1 with moderate to severe @entity227 registered with the Blind and @entity4064 Education Network New Zealand. The cohort was divided into two periods (1991-2004; 2005-2012) for analysis. RESULTS: 232 @entity1 with @entity989 were treated in the study period (109 in period 1, 123 in @entity5394 ). 36 @entity1 , 63.9% of whom were of male sex, were identified with subsequent significant @entity227 (27 in period 1, 9 in @entity5394 ). The incidence of new cases of @entity227 from @entity989 declined from 271.6 @entity1 /100   000 live very preterm births per annum (period 1) to 146.1 per annum ( @entity5394 ). Mean gestational age and mean birth weight were comparable between the two study periods. 75% of @entity1 with @entity227 from @entity989 received treatment for their condition (period 1, 74.1%; @entity5394 , 77.8%) and modalities used changed significantly over time. The modal visual outcome overall was Snellen visual acuity <6/18-6/60 (55.6%) (period 1, 51.9%; @entity5394 , 66.7%). The proportion of @entity1 with no light perception bilaterally decreased over time (period 1, 3.7%; @entity5394 , 0%). CONCLUSIONS: There has been a reduction in the incidence of @entity1 with significant @entity227 from @entity989 over time in New Zealand, likely due to progress in clinical management of @entity989 . Our study suggests the current @entity989 screening criteria of <31   weeks' gestation or <1250   g are of sufficient breadth.
